Chloroquine

A randomized controlled trial conducted by researchers at Wuhan UniversityWuhan University including 62 patients found that time to clinical recovery, based on clinical characteristics and radiological results 5 days after treatment, was significantly shortened in the hydroxychloroquine group.

A randomized controlled trial conducted by researchers at Wuhan University includedincluding 62 patients and found that time to clinical recovery, based on clinical characteristics and radiological results 5 days after treatment, was significantly shortened in the hydroxychloroquine group.

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have reported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier Raoult. Controls in the study were patients who refused treatment, had exclusion criteria and patients in other medical centers that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given the hydroxychloroquine and azithromycin combination.

A randomized controlled trial conducted by researchers at Wuhan University included 62 patients and found that time to clinical recovery, based on clinical characteristics and radiological results 5 days after treatment, was significantly shortened in the hydroxychloroquine group.

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have reported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier Raoult. The trial lacks a control group that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given the hydroxychloroquine and azithromycin combination.

TheA firstrandomized controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan University, Shanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in the time it took to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.

The first controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan University, ShanghaiShanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in time to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.

The first controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan UniversityFudan University, Shanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in time to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have reported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier RaoultDidier Raoult. The trial lacks a control group that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given hydroxychloroquine and azithromycin.

Chloroquine has been reported to be an effective antiviral therapeutic against COVID-19 in treatments done in China and South Korea, with clinical trialtrials ongoing as of March 2020. Treatment with chloroquine tablets was reported to show favorable outcomes such as faster time to recover and shorter hospital stay in people with COVID-19 infections. Laboratory research from the US CDC shows chloroquine also has potential to treat prophylactically. Chloroquine is being investigated to treat COVID-19 in the form of chloroquine phosphate or hydroxychloroquine sulfate which are sometimes referred to as chloroquine and hydroxychloroquine respectively.

As of March 26, 2020 the NIH Clinical Trials database showed 18 clinical trials listing hydroxychloroquine as an intervention. Hydroxychloroquine alone and in combination with the the antibiotic azithromycin (aka Zithromas or Azithrocin) have shownreported early evidence of being effective in treating COVID-19 in preliminary results in a small study on 30 patients in France, led by Didier Raoult. The trial lacks a control group that did not receive hydroxychloroquine. According to the paper Azithromycin was given to some patients to prevent bacterial super-infection. Azithromycin is also known to have immunomodulatory effects.It is not clear if differences between patients that received hydroxychoroquine alone and the combination therapy may be due to differences in the patient's viral load between the two groups. Subsequent results from Raoult's group have been released where all patients were given hydroxychloroquine and azithromycin.

The first controlled study, a randomized trial comparing patients treated with hydroxychloroquine and a control group with 30 patients performed by researchers at Fudan University, Shanghai. This study led by LU Hongzhou found no difference between the hydroxychloroquine and control groups in time to achieve negative throat swabs for the virus and normalization of body temperature and radiological progression by CT imaging. The authors noted that a larger sample size was needed to assess the effects of hydroxychloroquine on COVID-19.